Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.51 |
| ▸ | KDM5A | P29375 | 3/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.44 |
| ▸ | RPA1 | P27694 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095265 | 0.89 | KDM4C (0.62) | KDM4CKDM5BKDM5AKDM2BKDM4A | |
| SCHEMBL16095912 | 0.83 | KDM4C (0.61) | KDM4CKDM5BKDM5AKDM2B | |
| SCHEMBL16095163 | 0.81 | KDM4C (0.62) | KDM4CKDM5BKDM5AKDM2B | |
| SCHEMBL16095348 | 0.79 | KDM4C (0.63) | KDM4CKDM5BKDM5AKDM2BKDM4A | |
| SCHEMBL16095072 | 0.78 | KDM4C (0.65) | KDM4CKDM5BKDM5A | |
| SCHEMBL16034015 | 0.76 | KDM4C (1.00) | KDM4CKDM5BKDM5AKDM2BKDM4A | |
| SCHEMBL16095232 | 0.74 | KDM4C (0.48) | KDM4CKDM5BKDM5AKDM2B | |
| SCHEMBL16094315 | 0.74 | KDM4C (0.65) | KDM4CKDM5BKDM5AKDM2B | |
| SCHEMBL16095025 | 0.74 | KDM4C (0.65) | KDM4CKDM5BKDM5AKDM2B | |
| SCHEMBL16095181 | 0.74 | KDM5B (0.44) | KDM4CKDM5BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM5B 10/4885KDM5A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.